203. 22q11.2 deletion syndrome Clinical trials / Disease details


Clinical trials : 5 Drugs : 7 - (DrugBank : 1) / Drug target genes : 14 - Drug target pathways : 23

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-002011-61-NL
(EUCTR)
13/08/202121/06/2021Riluzole as treatment for psychotic and cognitive symptoms in 22q11.2 deletion syndromeThe glutamate/GABA balance as novel therapeutic target for psychotic and cognitive symptoms in 22q11.2 deletion syndrome - Riluzole in 22q11.2DS 22q11.2 deletion syndrome;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]Trade Name: Rilutek
Product Name: Riluzole
Product Code: EMEA/H/C/000109
Academisch ziekenhuis MaastrichtNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
45Phase 3Netherlands
2NCT05149898
(ClinicalTrials.gov)
March 3, 20205/10/2021Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion SyndromeOpen-Label, Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome22Q Deletion SyndromeDrug: ZYN002Zynerba Pharmaceuticals, Inc.NULLCompleted4 Years17 YearsAll20Phase 1/Phase 2United States;Australia
3NCT04639960
(ClinicalTrials.gov)
September 29, 20173/11/2020Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion SyndromeEffects of Modulation of the Dopaminergic System Using Risperidone on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome22q11.2 Deletion SyndromeDrug: Risperdal;Drug: PlaceboUniversity of Geneva, SwitzerlandNULLTerminated11 Years25 YearsAll16N/ASwitzerland
4NCT02895906
(ClinicalTrials.gov)
November 28, 201629/8/2016Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric ConditionsA 5-Week, Multi-center, Open-label Study to Assess the Safety and Efficacy of NFC-1 in Subjects Aged 12-17 Years With 22q11.2 Deletion Syndrome and Commonly Associated Neuropsychiatric Conditions (Anxiety, ADHD, ASD)22q11.2 Deletion SyndromeDrug: NFC-1Aevi Genomic Medicine, LLC, a Cerecor companyNULLCompleted12 Years17 YearsAll2Phase 1United States
5NCT04647500
(ClinicalTrials.gov)
August 26, 20163/11/2020Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion SyndromeEffects of Modulation of the Dopaminergic System Using Methylphenidate on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome22q11.2 Deletion SyndromeDrug: ConcertaUniversity of Geneva, SwitzerlandNULLCompleted8 Years25 YearsAll45N/ASwitzerland